Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apigenin-coated gold nanoparticles (Api-AuNPs) are an experimental therapeutic nanomaterial consisting of gold nanoparticles synthesized using the plant-derived flavonoid apigenin (4',5,7-trihydroxyflavone) as both a reducing and capping agent. This 'green synthesis' approach results in nanoparticles typically ranging from 19 to 90 nm in size. The compound is primarily investigated in preclinical academic research for its potential in oncology and cardioprotection. In cancer models, including colorectal, breast, and cholangiocarcinoma, Api-AuNPs induce apoptosis by modulating the Bax/Bcl-2 ratio and activating Caspase-3. Additionally, they have shown efficacy in reducing doxorubicin-induced cardiotoxicity by mitigating oxidative stress and inflammatory markers. The gold core also enables applications in photothermal therapy, where the particles convert light into heat to ablate tumor cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on apigenin-coated gold nanoparticles.